{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:35Z","timestamp":1793802515779,"version":"4.6.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017851","name":"Sebia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic monoclonal antibodies (t-mAbs) are widely used in oncology, hematology, and immune-mediated diseases. Some t-mAbs are detectable by serum protein electrophoresis (SPEP) and immunofixation (IF), potentially mimicking monoclonal gammopathies. Despite widespread use, migration profiles of many t-mAbs remain incompletely described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-six t-mAbs were tested using Sebia Capillarys 3 (SPEP) and Hydrasis (IF) systems. Normal human sera, free of electrophoretic abnormalities, were spiked with each t-mAb at its reported maximum therapeutic concentration (Cmax). Electropherogram data were processed with a Python-based workflow for axis alignment, standardized profile overlay, and visualization. T-mAbs not detected at Cmax were assessed at 500 mg\/L to determine their electrophoretic migration profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No interference was observed below 110 mg\/L. All t-mAbs tested above this threshold were detectable by SPEP and IF. Migration patterns were newly characterized for several t-mAbs, including bispecific and drug-conjugated antibodies, and confirmed for previously described agents. Overlay analysis enabled refined attribution of migration zones within alpha and beta regions. T-mAbs detectability was summarized in a consolidated table. A stepwise decision algorithm was developed to guide interpretation of suspected t-mAb\u2013related interference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study expands knowledge of t-mAb interference with SPEP and IF and provides standardized electrophoretic profiles for established and emerging therapies. The summary table and decision algorithm offer practical tools for clinical laboratories, facilitating interpretation of electrophoretic patterns, supporting differentiation between t-mAb and monoclonal gammopathies, and highlighting the need for continued characterization of novel t-mAbs entering routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvag080","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:40:43Z","timestamp":1784126443000},"page":"1171-1191","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of the Migration Profile of 36 Therapeutic Monoclonal Antibodies in Serum Protein Electrophoresis and Immunofixation"],"prefix":"10.1093","volume":"72","author":[{"given":"Sacha","family":"Pelletier","sequence":"first","affiliation":[{"name":"Laboratory of Biochemistry, University Hospital of Reims , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Cliquot","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, University Hospital of Reims , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Slimano","sequence":"additional","affiliation":[{"name":"BioSpecT, University of Reims Champagne-Ardenne , Reims ,","place":["France"]},{"name":"Pharmacy, University Hospital of Reims , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gillery","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, University Hospital of Reims , Reims ,","place":["France"]},{"name":"CNRS UMR N\u00b07369 MEDyC, University of Reims Champagne-Ardenne , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Florent","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, University Hospital of Reims , Reims ,","place":["France"]},{"name":"CNRS UMR N\u00b07369 MEDyC, University of Reims Champagne-Ardenne , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Oudart","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, University Hospital of Reims , Reims ,","place":["France"]},{"name":"CNRS UMR N\u00b07369 MEDyC, University of Reims Champagne-Ardenne , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026110408522626700_hvag080-B1","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2026110408522626700_hvag080-B2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"2026110408522626700_hvag080-B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib8010021","article-title":"Immunogenicity of innovative and biosimilar monoclonal antibodies","volume":"8","author":"Doevendans","year":"2019","journal-title":"Antibodies"},{"key":"2026110408522626700_hvag080-B4","first-page":"18","article-title":"Les anticorps monoclonaux\u202f: apprenons \u00e0 les conna\u00eetre","volume":"52","author":"Bardet","year":"2013","journal-title":"Actual Pharm"},{"key":"2026110408522626700_hvag080-B5","doi-asserted-by":"crossref","first-page":"2075078","DOI":"10.1080\/19420862.2022.2075078","article-title":"International nonproprietary names for monoclonal antibodies: an evolving nomenclature system","volume":"14","author":"Guimaraes Koch","year":"2022","journal-title":"mAbs"},{"key":"2026110408522626700_hvag080-B6","doi-asserted-by":"crossref","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"mAbs"},{"key":"2026110408522626700_hvag080-B7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jalm\/jfac064","article-title":"Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-derived interference in serum protein electrophoresis and immunofixation electrophoresis","volume":"7","author":"Scholl","year":"2022","journal-title":"J Appl Lab Med"},{"key":"2026110408522626700_hvag080-B8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11926-018-0799-0","article-title":"Review of biosimilar trials and data on etanercept in rheumatoid arthritis","volume":"20","author":"Chadwick","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2026110408522626700_hvag080-B9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/0897190015615248","article-title":"Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran","volume":"28","author":"Miyares","year":"2015","journal-title":"J Pharm Pract"},{"key":"2026110408522626700_hvag080-B10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/19420862.2018.1553476","article-title":"Structure, heterogeneity and developability assessment of therapeutic antibodies","volume":"11","author":"Xu","year":"2019","journal-title":"mAbs"},{"key":"2026110408522626700_hvag080-B11","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1515\/cclm-2025-0678","article-title":"Interference of therapeutic monoclonal antibodies with electrophoresis and immunofixation of serum proteins: state of knowledge and systematic review","volume":"63","author":"Pelletier","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"2026110408522626700_hvag080-B12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u201chigh-hanging fruit.\u201d","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2026110408522626700_hvag080-B13","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.380","article-title":"Pharmacokinetic equivalence, comparable safety, and immunogenicity of an Adalimumab biosimilar product (M923) to Humira in healthy subjects","volume":"6","author":"Hillson","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"2026110408522626700_hvag080-B14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fphar.2019.00905","article-title":"A phase I, randomized, single-dose study evaluating the biosimilarity of TAB008 to bevacizumab in healthy volunteers","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026110408522626700_hvag080-B15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2026110408522626700_hvag080-B16","first-page":"163","article-title":"Monoclonal antibody interference in electrophoresis","volume":"55","author":"Malik","year":"2023","journal-title":"Pathology (Phila)"},{"key":"2026110408522626700_hvag080-B17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1515\/cclm-2015-1023","article-title":"Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2026110408522626700_hvag080-B18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: first approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"key":"2026110408522626700_hvag080-B19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/psp4.12477","article-title":"Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors","volume":"9","author":"Sanghavi","year":"2020","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2026110408522626700_hvag080-B20","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/ijms25042203","article-title":"Clinical and real-world effectiveness of mogamulizumab: a narrative review","volume":"25","author":"Fern\u00e1ndez-Guarino","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026110408522626700_hvag080-B21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2026110408522626700_hvag080-B22","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J Neurol"},{"key":"2026110408522626700_hvag080-B23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40262-019-00842-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients","volume":"59","author":"Pang","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026110408522626700_hvag080-B24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1479-5876-10-236","article-title":"Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion","volume":"10","author":"Ribas","year":"2012","journal-title":"J Transl Med"},{"key":"2026110408522626700_hvag080-B25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026110408522626700_hvag080-B26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput Sci Eng"},{"key":"2026110408522626700_hvag080-B27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1515\/cclm-2019-1104","article-title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis","volume":"58","author":"Turner","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2026110408522626700_hvag080-B28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/cclm-2019-1105","article-title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins","volume":"58","author":"Jacobs","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2026110408522626700_hvag080-B29","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1515\/cclm-2013-0898","article-title":"Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins","volume":"52","author":"Ruinemans-Koerts","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2026110408522626700_hvag080-B30","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1373\/clinchem.2010.152116","article-title":"Interference of monoclonal antibody therapies with serum protein electrophoresis tests","volume":"56","author":"McCudden","year":"2010","journal-title":"Clin Chem"},{"key":"2026110408522626700_hvag080-B31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinbiochem.2016.09.015","article-title":"Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood","volume":"51","author":"Murata","year":"2018","journal-title":"Clin Biochem"},{"key":"2026110408522626700_hvag080-B32","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1515\/cclm-2021-0399","article-title":"Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference","volume":"59","author":"Noori","year":"2021","journal-title":"Clin Chem Lab Med"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/11\/1171\/68895324\/hvag080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/11\/1171\/68895324\/hvag080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:52:38Z","timestamp":1793800358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/72\/11\/1171\/8734892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvag080","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,7,15]]}}}